92001-52-0

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-8-methyl-purine is utilized as a key building block in the synthesis of various pharmaceutical compounds, including anti-cancer and anti-viral drugs. Its unique chemical structure allows for the development of novel therapeutic agents that can target specific biological pathways and mechanisms, offering potential benefits in the treatment of various diseases.
Used in Material Science:
In the field of material science, 6-chloro-8-methyl-purine has potential applications in the development of organic semiconductors. Its chemical properties and structure make it a promising candidate for use in the creation of advanced materials with unique electronic and optical properties, which can be applied in various technological applications, such as organic light-emitting diodes (OLEDs) and organic solar cells.

InChI:InChI=1/C6H5ClN4/c1-3-10-4-5(7)8-2-9-6(4)11-3/h2,4H,1H3

Upstream product

• 50609-15-9 5-acetylamino-4-amino-6-oxo-1,6-dihydropyrimidine 
• 1445-45-0 Trimethyl orthoacetate 
• 4316-98-7 6-chloro-4,5-diaminopyrimidine 
• 108-24-7 acetic anhydride 
• 218431-07-3 6,8-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 239784-24-8 6-chloro-8-methyl-9-(tetrahydro-2-hydro-pyran-2-yl)-9H-purine 

Downstream Products

• 22387-37-7 8-methyladenine 
• 1126-23-4 8-methyl-1,7-dihydro-purine-6-thione 
• 1008-51-1 8-methyl-6-methylsulfanyl-7(9)H-purine 
• 1393180-99-8 (S)-8-methyl-N-(1-(1-phenyl-1H-benzo[d]imidazol-2-yl)ethyl)-9H-purin-6-amine 

Relevant academic research and scientific papers

Design and optimization of purine derivatives as in vivo active PDE10A inhibitors

Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitors reported by Bartolome-Nebreda et al., we initialized a project for developing PDE10A inhibitors. After several rounds of optimization, we were able to obtain a few compounds with good PDE10A enzymatic activity. And after further PDE enzymatic selectivity study, metabolic stability assay and in vivo pharmacological tests we identified two inhibitors as interesting lead compounds with the potential for further PDE10A lead optimizatioin.

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Dichotomy in regioselective cross-coupling reactions of 6,8-dichloropurines with phenylboronic acid and methylmagnesium chloride: Synthesis of 6,8-di-substituted purines

Pd-catalyzed cross-coupling reaction of 6,8-dichloro-9-(tetrahydropyran-2- yl)purine with one equivalent of phenylboronic acid proceeded regioselectively to give 8-chloro-6-phenylpurine, while the analogous Fe-catalyzed reaction with methylmagnesium chlor

Specificity of the 1-Methyladenine Receptors in Starfish Oocytes: Synthesis and Properties of Some 1,8-Disubstituted Adenines, 1,6-Dimethyl-1H-purine, and of the 1-(Azidobenzyl)adenines

A selective synthesis of 1,6-dimethylpurine (16) and the preparations of the 1-(azidobenzyl)adenines (11)-(13), 8-azido-1-benzyladenine (10), and 1-methyladenine derivatives (2)-(9) with various 8-substituents (azido, chloro, bromo, alkyl, and hydroxymeth